Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

SCRI to lead clinical development of AstraZeneca's novel targeted oncology compound

AstraZeneca and Sarah Cannon Research Institute (SCRI), an international leader in advancing therapies for cancer patients through clinical research, today announced that SCRI will lead the clinical development of a novel targeted oncology compound from AstraZeneca.

12 Jan 2011

SciClone initiates phase 2b study of SCV-O7 for oral mucositis

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of the first patient in the company's phase 2b clinical trial of SCV-07 for the prevention of oral mucositis (OM) -- a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and neck cancer.

11 Jan 2011

Cyclacel opens enrollment of sapacitabine Phase 3 trial for AML

Cyclacel Pharmaceuticals, Inc., today announced that it has opened enrollment of the SEAMLESS pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment of elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

11 Jan 2011

Study supports use of telomerase inhibitors for treatment of childhood cancers

Geron Corporation today announced the publication of preclinical data demonstrating that the company's telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, selectively targets cancer stem cells in pediatric tumors of neural origin.

11 Jan 2011

BioScale announces results of two pharmacodynamic biomarkers using assay AMMP technology

BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.

11 Jan 2011

QIAGEN to acquire minority stake in Alacris Theranostics

QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.

From QIAGEN Manchester Limited 11 Jan 2011

Biologics receives National Comprehensive Cancer Network recognition

Biologics, Inc., an oncology management company, has been recognized by the National Comprehensive Cancer Network® (NCCN®) for its commitment to supporting patient access to quality oncology care. For the first time, the NCCN, a not-for-profit alliance of 21 of the world's leading cancer centers, is recognizing commercial payor and non-payor organizations, including Biologics, which support the appropriate, effective, and efficient use of oncology treatment and care of patients through its new NCCN Recognition Program.

11 Jan 2011

Nationwide Children's Hospital receives $11.5 million NCI grant for Biospecimen banking

Nationwide Children's Hospital was awarded $11.5 million from the National Cancer Institute late last year to continue its role as one of two Biospecimen Core Resources for The Cancer Genome Atlas.

11 Jan 2011

LibiGel may be the first FDA approved product to treat HSDD in menopausal women

BioSante Pharmaceuticals, Inc., a pharmaceutical company developing products for the treatment of female sexual health, today announced results of a survey of over 100 Obstetrician/Gynecologists and Primary Care Physicians regarding the need for an FDA-approved drug to treat a form of Female Sexual Dysfunction (FSD) known as Hypoactive Sexual Desire Disorder (HSDD).

11 Jan 2011

VCU Massey Cancer Center introduces safer, more effective form of radiation therapy

Virginia Commonwealth University Massey Cancer Center has introduced a safer and more effective form of radiation therapy to treat cancer. The Center now offers volumetric modulated arc therapy (VMAT) delivery using the Philips Pinnacle3 SmartArc software to provide radiation treatment for multiple tumor sites, including prostate, head and neck, brain, breast and lung. VCU Massey is the first cancer center in the Richmond area to offer this cutting-edge radiation technique.

10 Jan 2011

Enlight Biosciences forms new oral drug delivery technology company

Entrega, Inc., a new company developing oral drug delivery technologies, today announced its formation by Enlight Biosciences, a Boston-based company established in partnership with a group of leading global pharmaceutical companies.

10 Jan 2011

Emergent BioSolutions estimates total revenue of $285 to $288 million for 2010

Emergent BioSolutions Inc. announced today preliminary, unaudited financial results for 2010 and guidance for 2011.

10 Jan 2011

Takeda San Francisco and Pieris enter Anticalin scaffold technology collaboration

Takeda San Francisco (TSF) and Pieris AG have signed a drug discovery partnership agreement under which Pieris will apply its Anticalin(R) scaffold technology to deliver protein therapeutic candidates to Takeda, both companies announced today. The deal initially will focus on first-in-class drug discovery efforts around a predetermined Takeda target.

10 Jan 2011

LabCorp to market On-Q-ity's circulating tumor cell platform

On-Q-ity, a next-generation oncology diagnostics company developing personalized and predictive tests to improve cancer therapy effectiveness, today announced a strategic alliance with Laboratory Corporation of America Holdings® (LabCorp). LabCorp will market On-Q-ity's novel and proprietary circulating tumor cell (CTC) platform to the biopharma industry to greatly accelerate and improve the cancer drug discovery and development process.

10 Jan 2011

Endo Pharmaceuticals receives FDA complete response letter for OPANA ER

Endo Pharmaceuticals today announced that it received a complete response letter from the U.S. Food and Drug Administration regarding the New Drug Application for its new formulation of OPANA® ER designed to be crush resistant.

10 Jan 2011

FDA approves Abstral drug for treatment of breakthrough pain in cancer patients

Orexo AB announces today that its partner ProStrakan Group plc has received approval from the US Food and Drug Administration for Abstral. Abstral is licensed for the treatment of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving, and are tolerant to, opioid analgesics for their underlying persistent cancer pain.

10 Jan 2011

Anchor announces rapid progress in OMJPI collaboration for developing GPCR therapeutic compounds

Anchor Therapeutics today announced that it has successfully completed the first stage of its collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals.

10 Jan 2011

Anthem Blue Cross, Washington Hospital enter agreement to deliver quality care

Washington Hospital and Anthem Blue Cross today announced that they have reached an agreement which will continue the Hospital's delivery of quality care to Anthem members and the Tri-City community's access to its local hospital.

10 Jan 2011

Scientists identify type of cell at the origin of brain tumors

Scientists have identified the type of cell that is at the origin of brain tumors known as oligodendrogliomas, which are a type of glioma - a category that defines the most common type of malignant brain tumor.

7 Jan 2011

MMRF awards $3 million under 2010 Biotech Investment Awards program

The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded $1 million to each of three Boston-area biotech companies through its 2010 Biotech Investment Awards program: Constellation Pharmaceuticals, Inc., Epizyme, Inc. and Karyopharm Therapeutics, Inc. Since the inception of this MMRF program in 2006, $11 million has been committed to 11 biotech companies in multi-year, results-driven funding for the development of innovative treatments for patients with multiple myeloma.

7 Jan 2011